Meizhu, Set to List on KOSDAQ... Stable Performance Attracts Investor Attention

TechubNews · 2026-03-24T17:08:15+00:00

South Korean exchange approves medical device manufacturer Mezoo to list on the Kosdaq market, with trading expected to begin on the 26th. Mezoo achieved sales of 236.6 billion Korean won last year with operating profits of 595.1 billion Korean won, demonstrating stable growth. This listing will enhance its exposure and investor confidence, having a positive impact on business expansion.

TechubNews

2026-03-24 17:08:15

Abstract generation in progress

South Korean exchange approved the medical device manufacturer Mezoo for listing on the KOSDAQ market on the 24th. Mezoo is part of the technology growth enterprise sector within the KOSDAQ market and is expected to begin trading on the 26th of this month.

Mezoo is a highly regarded company in the medical device field, maintaining stable performance in recent years. In 2024, Mezoo achieved total sales of 23.66 billion KRW and an operating profit of 59.51 billion KRW, demonstrating continuous growth. This performance confirms the effectiveness of its new technology development and market expansion strategies.

Leading the listing of Mezoo is Shinhan Financial Investment Securities, which is optimistic about the company’s technological strength and growth potential, serving as the lead underwriter. This move is expected to positively impact Mezoo’s future business expansion and fundraising efforts. As KOSDAQ is a hub for tech companies, the listing of Mezoo is highly anticipated to generate significant reactions within the tech stock sector.

With this approval, Mezoo will gain exposure to a broader investor audience, which could help boost the company’s valuation and earn greater investor trust in the long run. Its performance on the KOSDAQ market will serve as an important indicator of Mezoo’s future growth trajectory.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.